Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RT-114 in Healthy Volunteers and Participants with Obesity
NCT06891287Phase 1Recruiting
- Sponsor
- Rani Therapeutics
- Start
- Dec 2025
- Primary completion
- Dec 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised trial of RT-114 in obesity (4 arms), sponsored by Rani Therapeutics. Primary endpoint: Treatment Emergent Adverse Events at 8 weeks. Started Dec 2025; status: recruiting.
02
Drugs
RT-114
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06891287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06891287.